Inmune Bio Stock Target Price and Analyst Consensus

INMB
 Stock
  

USD 9.41  0.29  3.18%   

The current analyst and expert consensus on Inmune Bio is Strong Buy, with 0 strong sell and 2 strong buy opinions. The current projected Inmune Bio target price consensus is 37.0 with 2 analyst opinions. The most common way Inmune Bio analysts use to provide recommendation to the public is financial statements analysis. Many experts also interview Inmune Bio executives and customers to further validate their buy or sell advice. Please note, the number of analysts providing the opinion is not sufficient to provide adequate consensus on Inmune Bio. We encourage you to use your own analysis of Inmune Bio to validate this buy or sell advice. Inmune Bio buy-or-sell recommendation module provides average expert sentiment on the projected Inmune Bio target price to derive its highest and lowest estimates based on projected price volatility of 7.071. Please see Macroaxis Advice on Inmune Bio to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon.
  
As of August 15, 2022, Gross Profit is expected to decline to about 150.8 K. Inmune Bio Receivables is projected to increase significantly based on the last few years of reporting. The past year's Receivables was at 4.91 Million. The current year Accounts Payable is expected to grow to about 4.1 M, whereas Accumulated Retained Earnings Deficit are forecasted to decline to (65.4 M).

Inmune Bio Target Price Consensus

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Inmune target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts performance other than comparing it to the past results via a very sophisticated attribution analysis. Inmune target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
Number of Opinions2
Lowered Outlook0
Raized Outlook0
Strong Buy
Most Inmune analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Inmune stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Inmune Bio, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice   Exposure   Valuation

Inmune Bio Target Price Projection

Inmune Bio's current and average target prices are 9.41 and 37.00, respectively. The current price of Inmune Bio is the price at which Inmune Bio is currently trading. On the other hand, Inmune Bio's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.

Current Price

Inmune Bio Market Quote on 15th of August 2022

Low Price9.21Odds
High Price9.48Odds

9.41

Target Price

Analyst Consensus On Inmune Bio Target Price

Low Estimate32.0Odds
High Estimate42.0Odds
Number of Analysts2
Standard Deviation7.071

37.0

Note that most analysts generally publish their price targets in research reports on specific companies, along with recommendations for the company's stock.Although price targets are often quoted in the financial news media, there could be a delay between the publication of the latest analyst outlook on Inmune Bio and the information provided on this page.

Inmune Bio Analyst Ratings

Inmune Bio's analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Inmune Bio stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Inmune Bio's financials, market performance, and future outlook by experienced professionals. Inmune Bio's historical ratings below, therefore, can serve as a valuable tool for investors.

Analyst Consensus Breakdown

Average Consensus Estimates

About Inmune Bio Target Price Projections

Inmune Bio's target price is an analyst's projection of its future price. Price targets can be assigned to all types of securities, from complex investment products to stocks such as Inmune Bio and even bonds. If the target price is unavailable, it is most likely because there were not enough analyst opinions to come up with a consensus estimate. When setting a price target estimate, an analyst is trying to determine what the Stock is worth and where the price will be in a year from now. Generally, the target price of Inmune depends on its intrinsic valuation, beta (i.e., risk over market), and overall volatility. Most analysts publish their price targets in research reports on specific companies, along with their buy, hold, or sell recommendations. Stock price targets are often quoted in the financial news media. Macroaxis uses multiple feeds to provide overall target price projection for Inmune Bio including analysis of its current option contracts.
Inmune Bio's latest option contracts expiring on 2022-08-19 are carrying combined implied volatility of 251.5 with a put-to-call open interest ratio of 0.32 over 12 outstanding agreements suggesting investors are buying way more calls than puts on contracts expiring on 2022-08-19. The current put volume is at 5, with calls trading at the volume of 35. This yields a 0.14 put-to-call volume ratio. The Inmune Bio option chain provides detailed quote and price information for the current Inmune Bio option contracts. It shows all of Inmune Bio's listed puts, calls, expiration dates, strike prices, and other pricing information.
Inmune Bio's stock options are financial instruments that give investors the right to buy or sell shares of Inmune Bio common stock at a specified price for a given time period. Generally speaking, an option to purchase or sell Inmune stock makes it part of the underlying stock when the option's price is tied to the movement of the underlying stock. If Inmune Bio's stock price goes up or down, the stock options follow.
Please see Macroaxis Advice on Inmune Bio to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon.

Inmune Bio In The Money Call Balance

When Inmune Bio's strike price is surpassing the current stock price, the option contract against Inmune Bio stock is said to be in the money. When it comes to buying Inmune Bio's options that are 'In the Money' or 'Out of the Money', the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
While 'out-of-the-money' option contracts written on Inmune Bio are typically viewed as the more aggressive, there are potential upsides to purchasing these types of options contracts. For one, the cost to buy an 'Out of the Money' option is lower than the cost to buy an 'In the Money' option. This cost-benefit is due to the fact that at the time of the purchase, 'Out of the Money' contracts have no intrinsic value. So, while the potential for a 100% loss is more significant, the cost and risk to enter the trade are lower.

Inmune Current Options Market Mood

Inmune Bio's open interest and total value indicators provide investors with the necessary information to digest the overall options buildup for its expiring contracts. In addition, it helps Inmune Stock's traders understand whether a recent fall or rise in the market is unreasonable and if the time has come to take contrarian positions. These ratios are calculated based on options trading volumes and current open interest.

Put-to-Call Open Interest

Put-to-Call Volume

Most options investors, including buyers and sellers of Inmune Bio's calls and puts, are not very successful. It is estimated that an average options trader loses somewhere between 80% to 90% of the time. Inmune Bio's option open interest and volume spread between outstanding puts and calls are regarded by many investors as reliable indicators of the overall future market direction. Using current Inmune Bio's option volume and open interest to make an investment decision is considered a contrarian-sentiment measure that can be utilized in many timing strategies in both derivative and spot marketplace.

Additional Inmune Bio Value Projection Modules

Most investment researchers agree that the mispricing and readjustment of any Stock value happens often and is sometimes even predictable, but there is no strong theory explaining why it happens. The current price of Inmune Bio is a key component of Inmune Bio valuation and have some predictive power on the future returns of a Inmune Bio.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Inmune Bio's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Inmune Bio in the context of predictive analytics.
Hype
Prediction
LowEstimated ValueHigh
3.579.4515.33
Details
Intrinsic
Valuation
LowReal ValueHigh
8.4716.2122.09
Details
Naive
Forecast
LowNext ValueHigh
8.6414.5220.40
Details
Earnings
Estimates (1)
LowProjected EPSHigh
-1.91-1.91-1.91
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Inmune Bio. Your research has to be compared to or analyzed against Inmune Bio's peers to derive any actionable benefits. When done correctly, Inmune Bio's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Inmune Bio.

Additional Inmune Bio Value Projection Modules

Most investment researchers agree that the mispricing and readjustment of any Stock value happens often and is sometimes even predictable, but there is no strong theory explaining why it happens. The current price of Inmune Bio is a key component of Inmune Bio valuation and have some predictive power on the future returns of a Inmune Bio.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Inmune Bio's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Inmune Bio in the context of predictive analytics.
Hype
Prediction
LowEstimated ValueHigh
3.579.4515.33
Details
Intrinsic
Valuation
LowReal ValueHigh
8.4716.2122.09
Details
Naive
Forecast
LowNext ValueHigh
8.6414.5220.40
Details
Earnings
Estimates (1)
LowProjected EPSHigh
-1.91-1.91-1.91
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Inmune Bio. Your research has to be compared to or analyzed against Inmune Bio's peers to derive any actionable benefits. When done correctly, Inmune Bio's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Inmune Bio.

Trending Themes

If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment.
Macroaxis Index
Invested few shares
Artificial Intelligence
Invested few shares
Chemicals
Invested over 40 shares
Momentum
Invested over 20 shares
Automobiles and Trucks
Invested over 100 shares
Impulse
Invested over 100 shares
Please see Macroaxis Advice on Inmune Bio to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. Note that the Inmune Bio information on this page should be used as a complementary analysis to other Inmune Bio's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.

Complementary Tools for Inmune Stock analysis

When running Inmune Bio price analysis, check to measure Inmune Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inmune Bio is operating at the current time. Most of Inmune Bio's value examination focuses on studying past and present price action to predict the probability of Inmune Bio's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Inmune Bio's price. Additionally, you may evaluate how the addition of Inmune Bio to your portfolios can decrease your overall portfolio volatility.
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
The data published in Inmune Bio's official financial statements usually reflect Inmune Bio's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Inmune Bio. For example, before you start analyzing numbers published by Inmune accountants, it's critical to develop an understanding of what Inmune Bio's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Inmune Bio's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Inmune Bio's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Inmune Bio's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Inmune Bio. Please utilize our Beneish M Score to check the likelihood of Inmune Bio's management to manipulate its earnings.